Rain Oncology Inc.
(NASDAQ GS: RAIN)
Rigrodsky Law, P.A. is investigating Rain Oncology Inc. (“Rain”) regarding possible breaches of fiduciary duties and other violations of law related to Rain’s agreement to be acquired by Pathos AI, Inc. Under the terms of the agreement, Rain shareholders will receive $1.16 per share in cash plus a non-tradeable contingent value right.